Looking at the characteristics of the DCIS, in the Group Européen de Curiethérapie/European Society for Radiotherapy and Oncology (GEC-ESTRO) trial [73] only low- and intermediate-risk DCIS (Van nuys Prognostic index = 8) with 5 mm clear surgical margins were eligible, while in the National Surgical Breast and Bowel Project B-39 Trial, all the types of DCIS were allowed, including 28% grade 3 and 12% hormonal receptor-negative tumours [74]. The gene discussed is NR4A1; the disease is ductal breast carcinoma in situ.